Arcutis Biotherapeutics, Inc.
No enriched coverage for $ARQT in the last 7 days.
No SEC Form 4 filings for $ARQT in the last 30 days.
Arcutis Biotherapeutics (ARQT) officer Patrick Burnett sold 222 shares of common stock at $21.05 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of his Restricted Stock Units. After the transaction, Burnett directly owns 120,244 shares, indicating the sale was a compensation-related tax event and not a discretionary reduction in his investment.
Arcutis Biotherapeutics, Inc. (ARQT) CFO Latha Vairavan sold 435 shares of common stock at $21.05 per share to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Ms. Vairavan directly holds 85,978 common shares. This sale is a routine tax-related event and not a discretionary market trade.
Arcutis Biotherapeutics, Inc. announced it will report its first quarter 2026 financial results and provide a business update on May 6, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast the same day at 4:30 PM ET, with a replay available on its investor website. Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a growing portfolio for inflammatory skin diseases.
